A new HIV drug that will cost Ksh5.1 million for the first two shots has been approved by the United States Food and Drug Administration (FDA).
The drug, which will be administered in form of two shots, will also require patients to partake yearly booster shots costing Ksh4.7 million each.
According to the FDA, the drug known as Sunlenca will be only administered to HIV-positive adults.
The drug functions by obstructing the capsid protein coat of the HIV-1 virus, interfering with the viral life cycle.
In a clinical trial, 83 percent of patients taking Sunlenca with a combination of other drugs achieved an undetectable viral load. This accounted for approval of the drug by United States Food and Drug Administration.Though the drug is so expensive.
The medication which is strictly for adults patients living with HIV-1, whose HIV infection cannot be treated with other available treatments due to resistance, intolerance or safety considerations.
Content created and supplied by: Managu (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More